These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26716419)

  • 1. FZD7 regulates BMSCs-mediated protection of CML cells.
    Liu N; Zang S; Liu Y; Wang Y; Li W; Liu Q; Ji M; Ma D; Ji C
    Oncotarget; 2016 Feb; 7(5):6175-87. PubMed ID: 26716419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
    Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
    Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
    Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
    Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
    Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Connexin 43-modified bone marrow stromal cells reverse the imatinib resistance of K562 cells via Ca 2+ -dependent gap junction intercellular communication.
    Li X; Xiao Y; Wang X; Huang R; Wang R; Deng Y; Rao J; Gao Q; Yang S; Zhang X
    Chin Med J (Engl); 2023 Jan; 136(2):194-206. PubMed ID: 36801891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
    Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
    Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor.
    Nagao R; Ashihara E; Kimura S; Strovel JW; Yao H; Takeuchi M; Tanaka R; Hayashi Y; Hirai H; Padia J; Strand K; Maekawa T
    Cancer Lett; 2011 Dec; 312(1):91-100. PubMed ID: 21906872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells.
    Zhang JF; Xu N; Du QF; Li R; Liu XL
    Blood Cells Mol Dis; 2016 Jul; 59():58-62. PubMed ID: 27282569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Wei YL; Liang Y; Xu L; Zhao XY
    Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spred2 modulates the erythroid differentiation induced by imatinib in chronic myeloid leukemia cells.
    Yang Y; Liu X; Xiao F; Xue S; Xu Q; Yin Y; Sun H; Xu J; Wang H; Zhang Q; Wang H; Wang L
    PLoS One; 2015; 10(2):e0117573. PubMed ID: 25688862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
    Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
    Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway.
    Liu Y; Song B; Wei Y; Chen F; Chi Y; Fan H; Liu N; Li Z; Han Z; Ma F
    Cytotherapy; 2018 Feb; 20(2):181-188. PubMed ID: 29269240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia.
    Zhang X; Tu H; Yang Y; Wan Q; Fang L; Wu Q; Li J
    Int J Hematol; 2016 Sep; 104(3):358-67. PubMed ID: 27272942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways.
    Kumar A; Bhattacharyya J; Jaganathan BG
    Sci Rep; 2017 Aug; 7(1):9535. PubMed ID: 28842696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells.
    Wu J; Wei B; Wang Q; Ding Y; Deng Z; Lu X; Li Y
    Cell Biochem Biophys; 2016 Jun; 74(2):277-83. PubMed ID: 26912059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
    He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
    Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate.
    Jørgensen HG; Allan EK; Mountford JC; Richmond L; Harrison S; Elliott MA; Holyoake TL
    Exp Hematol; 2005 Oct; 33(10):1140-6. PubMed ID: 16219536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
    Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T
    Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.